Table 1.
Demographic and clinical characteristics of the COMBINE, PREDICT, and CITA participants included in the pharmacogenomics GWAS.
| COMBINE | PREDICT | CITA | ||
|---|---|---|---|---|
| Sample sizes | p value | |||
| Total N | 498 | 266 | 319 | |
| Acamprosate N | 223 | 110 | 319 | |
| Naltrexone N | 199 | 102 | – | |
| Placebo only or no pills N | 177 | 54 | – | |
| Age, mean(SD) | 45.4 (10.6) | 45.2 (8.5) | 43.4 (11.6) | 0.012 |
| Sex, male N(%) | 343 (68.9%) | 266 (100%) | 204 (64.0%) | <0.0001 |
| Age of onset | 30.5 (11.9) | 30.2 (10.2) | 29.6 (12.0) | 0.63 |
| Baseline alcohol consumptiona, mean (sd) | ||||
| Days since last drinking day | 8.0 (5.4) | 22.0 (4.3) | 19.7 (8.8) | <0.0001 |
| Average number of drinks per drinking day | 12.1 (7.4) | 21.0 (12.7) | 12.0 (8.6) | <0.0001 |
| % Drinking daysb | 56.2 (22.8) | 82.0 (26.8) | 32.2 (28.2) | <0.0001 |
| % heavy drinking days | 47.2 (23.8) | 79.4 (27.9) | 28.6 (26.8) | <0.0001 |
| Treatment Outcomes: | ||||
| Relapse, N (%) | 380 (76.3%) | 158 (59.4%) | 101 (31.7%) | <0.0001 |
| Relapse in acamprosate subset, N (%) | 167 (74.9%) | 62 (56.4%) | 101 (31.7%) | <0.0001 |
| Relapse in naltrexone subset, N (%) | 146 (73.4%) | 65 (63.7%) | – | 0.084 |
| Heavy Relapse, N (%) | 338 (67.9%) | 142 (53.4%) | 84 (26.3%) | <0.0001 |
| Heavy relapse in acamprosate subset, N (%) | 144 (64.6%) | 56 (50.9%) | 84 (26.3%) | <0.0001 |
| Heavy relapse in naltrexone subset, N (%) | 127 (63.8%) | 57 (55.9%) | – | 0.18 |
aBaseline alcohol consumption measures are based on 30 days before start of treatment.
b% drinking days = 100 − % days abstinent in the 30 days before start of treatment.